News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Daily News Early Redo TAVI Outcomes Look Good, but ‘Far From Definitive’ Michael O'Riordan July 18, 2022
News Daily News Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy L.A. McKeown June 01, 2022
News Conference News EuroPCR 2022 Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot Michael O'Riordan May 23, 2022
News Conference News SCAI 2022 DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year L.A. McKeown May 23, 2022
News Conference News ACC 2022 Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD L.A. McKeown April 04, 2022